Status:
COMPLETED
Multicentric Prospective Validation of the Zurich Pituitary Score
Lead Sponsor:
University of Zurich
Conditions:
Pituitary Adenoma
Eligibility:
All Genders
Brief Summary
Predictive analytics for GTR, EOR and RV are useful in surgical decision-making, particularly whenever there is no unequivocal indication for surgery. Several factors have been shown to have a role in...
Detailed Description
In transsphenoidal surgery (TSS) for pituitary adenoma (PA), gross total resection (GTR) is often the target since it has been shown to relevantly influence long term patient outcome. This applies bot...
Eligibility Criteria
Inclusion
- Patients harboring suspected pituitary adenoma.
- Patients undergoing endoscopic transsphenoidal surgery
- Preoperative MRI including at least one volumetric sequence (i.e. MPRAGE or SPGR) with gadolinium with possibility for coronal reconstructions
- Postoperative MRI (2-4 months postoperative) including at least one volumetric sequence (i.e. MPRAGE or SPGR) with Gadolinium with possibility for coronal reconstructions
Exclusion
- Patients undergoing combined or transcranial operations
- Patients for whom a biopsy only is planned
- Patients by whom histology does not confirm the diagnosis of pituitary adenoma
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT04076046
Start Date
November 1 2019
End Date
December 1 2021
Last Update
December 17 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York, New York, United States, 11030
2
Department of Neurosurgery, Kepler Universitäts Klinikum
Linz, Austria
3
Toronto Western Hospital, University of Toronto
Toronto, Canada
4
Department of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital
Prague, Czechia